Patient Group Direction for COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [recombinant])

Document first published:
Page updated:
Publication type:

This Patient Group Direction (PGD) is for the administration of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) to individuals in accordance with the national COVID-19 vaccination programme.

Published 6 January 2021, updated 23 March, 28 April and 18 May 2021.